{"id":"NCT01147250","sponsor":"Sanofi","briefTitle":"Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2015-02","completion":"2015-02","firstPosted":"2010-06-22","resultsPosted":"2016-10-14","lastUpdate":"2016-12-20"},"enrollment":6068,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Coronary Syndrome"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":["Lyxumia"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Lixisenatide","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\n\\- To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina) compared to placebo in type 2 diabetic participants who recently experienced an acute coronary syndrome (ACS) event.\n\nSecondary Objectives:\n\nTo demonstrate that when compared to placebo, lixisenatide can reduce:\n\n* composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, or hospitalization for heart failure.\n* composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization procedure.\n* urinary albumin excretion (based on the urinary albumin/creatinine ratio).\n\nTo assess the safety and tolerability of lixisenatide.","primaryOutcome":{"measure":"Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina","timeFrame":"From randomization up to the end of study (median follow-up of 25 months)","effectByArm":[{"arm":"Placebo","deltaMin":399,"sd":null},{"arm":"Lixisenatide","deltaMin":406,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.8542"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":829,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Denmark","Ecuador","Egypt","Estonia","Finland","France","Georgia","Germany","Guatemala","India","Israel","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Norway","Panama","Peru","Philippines","Poland","Portugal","Romania","Russia","Serbia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Tunisia","Turkey (TÃ¼rkiye)","Ukraine","United Arab Emirates","United Kingdom"]},"refs":{"pmids":["25965710","26630143","39963952","36546588","35817031","33046070","32212368","30648112","30292589","29693361","28554908","23537041"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":669,"n":3032},"commonTop":["Hypoglycaemia","Nausea","Diarrhoea","Dizziness","Angina pectoris"]}}